IRADIMED CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IRADIMED CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $83.81M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $73.24M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $65.56M | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | $53.30M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $41.81M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $31.72M | Mar 4, 2022 |
| FY2021 | Dec 31, 2019 | $38.52M | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $30.44M | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $23.08M | Mar 6, 2020 |
| FY2018 | Dec 31, 2016 | $32.50M | Mar 7, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $83.81M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $73.24M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $65.56M | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | $53.30M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $41.81M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $31.72M | Mar 4, 2022 |
| FY2021 | Dec 31, 2019 | $38.52M | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $30.44M | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $23.08M | Mar 6, 2020 |
| FY2018 | Dec 31, 2016 | $32.50M | Mar 7, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.32M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $56.35M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $50.16M | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | $41.28M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $32.05M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $23.57M | Mar 4, 2022 |
| FY2021 | Dec 31, 2019 | $29.70M | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $23.23M | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $17.51M | Mar 6, 2020 |
| FY2018 | Dec 31, 2016 | $26.34M | Mar 7, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.48M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $19.23M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $17.19M | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | $12.83M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $9.33M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $1.37M | Mar 4, 2022 |
| FY2021 | Dec 31, 2019 | $9.63M | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $6.30M | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $499.8K | Mar 6, 2020 |
| FY2018 | Dec 31, 2016 | $7.21M | Mar 7, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.15M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $21.97M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $20.04M | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | $15.63M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $9.82M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($756.1K) | Mar 4, 2022 |
| FY2021 | Dec 31, 2019 | $8.65M | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $6.00M | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $1.29M | Mar 6, 2020 |
| FY2018 | Dec 31, 2016 | $10.92M | Mar 7, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.98M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $2.83M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $2.86M | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | $2.28M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.91M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $1.90M | Mar 4, 2022 |
| FY2021 | Dec 31, 2019 | $1.43M | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $1.52M | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $1.72M | Mar 6, 2020 |
| FY2018 | Dec 31, 2016 | $1.35M | Mar 7, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.95M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $25.62M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $13.47M | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | $10.04M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $11.26M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $5.82M | Mar 4, 2022 |
| FY2021 | Dec 31, 2019 | $10.23M | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $7.38M | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $3.42M | Mar 6, 2020 |
| FY2018 | Dec 31, 2016 | $9.41M | Mar 7, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.77M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $8.01M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $7.44M | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | $823.0K | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $482.3K | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $443.0K | Mar 4, 2022 |
| FY2021 | Dec 31, 2019 | $368.3K | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $228.3K | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $775.6K | Mar 6, 2020 |
| FY2018 | Dec 31, 2016 | $780.8K | Mar 7, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $108.78M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $98.33M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $92.16M | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | $85.51M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $82.88M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $71.07M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | $66.73M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $48.44M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $39.01M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $37.19M | Mar 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.16M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $11.51M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $20.74M | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | $11.84M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $10.71M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $9.68M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | $11.20M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $6.50M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $6.08M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $5.31M | Mar 8, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.62M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $86.82M | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $71.42M | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | $73.67M | Sep 3, 2025 |
| FY2023 | Dec 31, 2021 | $72.17M | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | $61.38M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $55.52M | Mar 4, 2022 |
| FY2021 | Dec 31, 2018 | $41.95M | Mar 4, 2022 |
| FY2020 | Dec 31, 2017 | $32.93M | Mar 5, 2021 |
| FY2019 | Dec 31, 2016 | $31.89M | Mar 6, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.23M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $56.79M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $43.26M | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | $47.26M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $46.99M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $37.67M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | $36.30M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $26.67M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $20.36M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $19.87M | Mar 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.16M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $52.23M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $49.76M | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | $57.96M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $62.00M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $50.07M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | $43.48M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $28.03M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $18.21M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $17.71M | Mar 8, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | 1 | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | 1 | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 4, 2022 |
| FY2021 | Dec 31, 2019 | 0 | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Mar 6, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Mar 7, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | 1 | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | 1 | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 4, 2022 |
| FY2021 | Dec 31, 2019 | 0 | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Mar 6, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Mar 7, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 12.78M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 12.71M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | 12.66M | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | 12.59M | Mar 1, 2024 |
| FY2021 | Dec 31, 2021 | 12.54M | Mar 4, 2022 |
| FY2021 | Dec 31, 2020 | 12.31M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | 11.77M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | 10.99M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | 10.60M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | 10.72M | Mar 8, 2018 |